Frontiers in Clinical Drug Research - Alzheimer Disorders- Impact Score, Ranking, SJR, h-index, Citescore, Rating, Publisher, ISSN, and Other Important Details

About Frontiers in Clinical Drug Research - Alzheimer Disorders

Frontiers in Clinical Drug Research - Alzheimer Disorders is a book series published by Bentham Science Publishers B.V.. This book series covers the area[s] related to Pharmaceutical Science, Neurology (clinical), Pharmacology (medical), Psychiatry and Mental Health, etc. The coverage history of this book series is as follows: 2019. The rank of this book series is 11956. This book series's impact score, h-index, and SJR are 0.00, 3, and 0.423, respectively. The ISSN of this book series is/are as follows: 22145168, 24518743.

The best quartile of Frontiers in Clinical Drug Research - Alzheimer Disorders is Q2. This book series has received a total of 7 citations during the last three years (Preceding 2022).

Frontiers in Clinical Drug Research - Alzheimer Disorders Impact Score 2022-2023

The latest impact score (IS) of the Frontiers in Clinical Drug Research - Alzheimer Disorders is 0.00. It is computed in the year 2023 as per its definition and based on Scopus data.

The impact score (IS), also denoted as the Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Frontiers in Clinical Drug Research - Alzheimer Disorders h-index

 

The h-index of Frontiers in Clinical Drug Research - Alzheimer Disorders is 3. By definition of the h-index, this book series has at least 3 published articles with more than 3 citations.

What is h-index?

The h-index (also known as the Hirsch index or Hirsh index) is a scientometric parameter used to evaluate the scientific impact of the publications and journals. It is defined as the maximum value of h such that the given Journal has published at least h papers and each has at least h citations.

Frontiers in Clinical Drug Research - Alzheimer Disorders ISSN

The International Standard Serial Number (ISSN) of Frontiers in Clinical Drug Research - Alzheimer Disorders is/are as follows: 22145168, 24518743.

The ISSN is a unique 8-digit identifier for a specific publication like Magazine or Journal. The ISSN is used in the postal system and in the publishing world to identify the articles that are published in journals, magazines, newsletters, etc. This is the number assigned to your article by the publisher, and it is the one you will use to reference your article within the library catalogues.

ISSN code (also called as "ISSN structure" or "ISSN syntax") can be expressed as follows: NNNN-NNNC
Here, N is in the set {0,1,2,3...,9}, a digit character, and C is in {0,1,2,3,...,9,X}

Frontiers in Clinical Drug Research - Alzheimer Disorders Ranking and SCImago Journal Rank (SJR)

The Frontiers in Clinical Drug Research - Alzheimer Disorders is ranked 11956 among 27955 Journals, Conferences, and Book Series. As per SJR, this book series is ranked 0.423.

SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

Frontiers in Clinical Drug Research - Alzheimer Disorders Publisher

The publisher of Frontiers in Clinical Drug Research - Alzheimer Disorders is Bentham Science Publishers B.V.. The publishing house of this book series is located in the Netherlands. Its coverage history is as follows: 2019.

Call For Papers (CFPs)

Please check the official website of this book series to find out the complete details and Call For Papers (CFPs).

Abbreviation

The International Organization for Standardization 4 (ISO 4) abbreviation of Frontiers in Clinical Drug Research - Alzheimer Disorders is Front. Clin. Drug Res. - Alzheimer Disord.. ISO 4 is an international standard which defines a uniform and consistent system for the abbreviation of serial publication titles, which are published regularly. The primary use of ISO 4 is to abbreviate or shorten the names of scientific journals using the technique of List of Title Word Abbreviations (LTWA).

As ISO 4 is an international standard, the abbreviation ('Front. Clin. Drug Res. - Alzheimer Disord.') can be used for citing, indexing, abstraction, and referencing purposes.

How to publish in Frontiers in Clinical Drug Research - Alzheimer Disorders

If your area of research or discipline is related to Pharmaceutical Science, Neurology (clinical), Pharmacology (medical), Psychiatry and Mental Health, etc., please check the book series's official website to understand the complete publication process.

Acceptance Rate

There are several factors that influence the acceptance rate of any academic journal. Here are some critical parameters that are considered while calculating the acceptance rate:

• Interest/demand of researchers/scientists for publishing in a specific journal/conference.
• The complexity of the peer review process and timeline.
• Time taken from draft submission to final publication.
• Number of submissions received and acceptance slots
• And Many More.

The simplest way to find out the acceptance rate or rejection rate of a Journal/Conference is to check with the journal's/conference's editorial team through emails or through the official website.

Credits and Sources

• Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
• Journal Impact Factor, https://clarivate.com/
• Issn.org, https://www.issn.org/
• Scopus, https://www.scopus.com/